Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child aged 1 year old (12-15 months old);~* Proven legal identity;~* The subjects'guardians should be capable of understanding the informed consent form, and such form should be signed prior to enrolment.~Exclusion Criteria:~* History of vaccination of varicella vaccine or hepatitis A vaccine.~* Previous history of varicella infection or hepatitis A infection;~* History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;~* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;~* Thyroid disease or history of thyroidectomy, asplenia,functional asplenia,asplenia or splenectomy resulting from any condition;~* Suffering from serious chronic diseases, serious cardiovascular diseases, liver and kidney diseases, malignant tumors, etc;~* Family history of psychosis,severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;~* Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;~* Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) within 6 months before enrollment;~* Receipt of blood products within the past 3 months;~* Receipt of other investigational vaccines or drugs within 28 days prior to receiving the investigational vaccine;~* Receipt of attenuated live vaccines in the past 28 days;~* Receipt of inactivated or subunit vaccines in the past 7 days;~* Onset of various acute or chronic diseases within 7 days prior to the study;~* Armpit temperature in subjects with fever prior to vaccination with the investigational vaccine. 37.4 ℃;~* According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- The combined immunization group (Type: EXPERIMENTAL): 225 participants received one dose of live attenuated varicella vaccine and the first dose inactivated hepatitis A vaccine on day 0 and the second dose of inactivated hepatitis A vaccine on day 180.
- The Non-combined immunization group (Type: ACTIVE_COMPARATOR): 225 participants received one dose of live attenuated varicella vaccine on day 0,the first dose of inactivated hepatitis A vaccine on day 42 and the second dose of inactivated hepatitis A vaccine on day 222.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete